Joinn Laboratories News

JOINN: 2024 ANNUAL REPORT

HKEXApr 29 06:45 ET · Announcements

Zhitong Hong Kong Stock Early Knowledge | The Ministry of Industry and Information Technology released the key points of automotive standardization work for 2025, ahead of schedule conducting research on the standardization needs of new business formats s

The Ministry of Industry and Information Technology released the key points for vehicle standardization work in 2025. It proposed to proactively layout standards research in cutting-edge fields. Analyzing and assessing the development trends of cutting-edge technologies and potential application scenarios, identifying and evaluating the future direction of vehicle standardization development, promoting the formulation and release of standard sub-systems for automotive AI, Solid State Battery, electric vehicle battery swapping, and initiating the construction of standard systems for new fields such as data governance and application, while conducting advanced research on standardization needs for new business formats like flying cars.

Zhitong FinanceApr 28 19:25 ET

Earnings Preview: JOINN to Report Financial Results on April 29

Moomoo NewsApr 28 18:45 ET

Zhaoyan Pharmaceutical: Zhaoyan New Pharmaceutical Report for the First Quarter of 2025

SZSIApr 28 12:00 ET · Announcements

Zhaoyan New Pharmaceutical Report for the First Quarter of 2025

SZSIApr 28 12:00 ET · Announcements

Express News | Joinn Laboratories China Co Ltd - Qtrly Net Profit Attributable RMB41.1 Mln

ReutersApr 28 09:18 ET

JOINN: 2025 FIRST QUARTERLY REPORT

HKEXApr 28 09:16 ET · Announcements

The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.

A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.

Zhitong FinanceApr 25 23:38 ET

Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.

① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?

cls.cnApr 24 03:37 ET

Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.

① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?

cls.cnApr 21 23:57 ET

Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.

As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.

cls.cnApr 16 20:31 ET

Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.

Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.

Zhitong FinanceApr 15 23:24 ET

Hong Kong stocks close | Under the shadow of tariffs, major indices performed unevenly. ZHOU HEI YA surged nearly 8%, leading the Consumer stocks to break through.

① How did Trump's tariff policy lead to a divergence in the Hong Kong stock market? ② Why does HTSC still recommend allocating to Hong Kong stock dividend direction despite tariff disruptions?

cls.cnApr 15 04:44 ET

Caitong: Innovative Drugs and Medical Devices remain an important main line in this round of the bull market in the Medical industry.

The country is likely to accelerate the introduction of policies to encourage expanded domestic demand, which is Bullish for the sectors focused on domestic consumption, including Traditional Chinese Medicine, Medical Services, Internet medicine and pharmacies, medical aesthetics, etc., as an extension of the Health China logic.

Zhitong FinanceApr 14 23:50 ET

Tariffs Loom as US Investigates Drug and Chip Imports

Business TodayApr 14 21:38 ET

Sinolink: Innovative Drugs will be the main growth line in the Pharmaceutical Sector, bringing investment opportunities for left-side sector stocks after the Q1 report.

The reversal of market conditions and improvement in performance after the quarterly report will also bring investment opportunities in individual stocks in sectors such as chain pharmacies, Medical Devices, CXO, generic drugs, Traditional Chinese Medicine, and Medical Services, and it is recommended to increase investment.

Zhitong FinanceApr 14 21:35 ET

Statistics on the changes in the proportion of Hong Kong Stock Connect on April 15.

Statistics on the changes in the proportion of Zhitong Hong Kong Stock Connect | April 14, 2025.

Zhitong FinanceApr 14 20:36 ET

Brokerage morning meeting highlights: The short-term bottom of the A-shares has already formed, looking for structural opportunities amid fluctuations.

At today's Brokerage morning meeting, Everbright believes that the market may mainly feature structural trends and hot sector rotations; Sinolink stated that they remain Bullish on the growth potential of Innovative Drugs companies in the Hong Kong and A shares markets; Galaxy Securities indicated that a short-term bottom in A shares has already formed and is seeking structural opportunities amidst the fluctuations.

cls.cnApr 14 20:14 ET

Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.

① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.

cls.cnApr 14 20:14 ET

Joinn Laboratories (06127.HK) subscribed to financial products worth 0.4 billion yuan.

Gelonghui April 14丨Joinn Laboratories (06127.HK) announced that on April 14, 2025, the group member companies subscribed through CITIC SEC and its subsidiaries for a total investment amount of 0.4 billion yuan in such CITIC SEC financial products, which have not yet matured as of the announcement date.

Gelonghui FinanceApr 14 09:27 ET